Peptide "stacking" — combining multiple peptides in a single research protocol — is one of the most common practices in this space and one of the least systematically studied. The published research literature has good data on individual compounds but limited controlled data on combinations. This thread is an overview of why researchers stack, what the most common combinations are, and what the practice looks like when done with discipline rather than as kitchen-sink experimentation.
Why combine peptides at all.
The rational case for combining peptides falls into three categories.
Mechanism complementarity. Different peptides target different pathways that converge on related outcomes. The classic example is BPC-157 (vascular and growth factor effects) combined with TB-500 (cell migration and recruitment) for tissue repair research — the two compounds work through different mechanisms and the combined effect addresses repair from complementary angles. The recovery stack and healing stack threads in this category cover this in detail.
Pharmacokinetic synergy. Some receptor systems exhibit synergistic activation when stimulated by two ligands targeting different but related receptors. The clearest example is the GHRH analog plus ghrelin mimetic combination (CJC-1295 + ipamorelin or similar) — the two compounds activate different pituitary pathways that synergize for greater GH release than either alone. The Mechanism + Half-Life thread covers the pharmacological basis.
Different effect timelines. Some protocols combine a fast-acting and a long-acting compound to provide both acute and sustained effects. Some protocols combine a protective compound with an active compound where the protective component manages a side effect of the active.
The common combinations researchers actually use.
Recovery and tissue repair. BPC-157 + TB-500 is the foundational combination. Some protocols extend this to BPC-157 + TB-500 + GHK-Cu (adding copper-mediated tissue effects) or BPC-157 + TB-500 + ipamorelin (adding GH-mediated recovery effects). These combinations have detailed threads in the Stacks & Protocols category.
Growth hormone optimization. CJC-1295 + ipamorelin (or another GHRH analog plus another ghrelin mimetic) is the dominant GH combination. Tesamorelin + ipamorelin is a less common variant. The combination produces stronger GH pulses than either alone.
Body recomposition. GLP-1 peptides (semaglutide or tirzepatide) combined with GH peptides (typically CJC-1295 + ipamorelin) is being studied for body composition outcomes that combine fat loss from GLP-1 effects with lean mass support from GH-mediated effects. The cross-category recomp thread covers protocol design considerations.
Healing and athletic recovery. The recovery stack (BPC-157 + TB-500 + GHK-Cu + ipamorelin) is one of the most-discussed combinations on the platform and is the focus of a dedicated thread. The combination targets tissue repair (BPC-157, TB-500, GHK-Cu) plus systemic recovery (ipamorelin GH effects).
Cosmetic combinations. Topical GHK-Cu combined with other cosmetic peptides for skin or hair endpoints. Less standardized than the medicinal combinations but documented in some research protocols.
Cognitive combinations. Semax + Selank (intranasal) for combined cognitive and stress endpoints. Less standardized and less studied than the medicinal combinations.
The discipline that distinguishes good combinations from kitchen-sink stacking.
A well-designed combination protocol has explicit answers to several questions.
What is each compound doing in the protocol? Every compound in a stack should have a specific reason for being there. "I added X because someone on a forum said it helps" is not a reason. "I added X because its mechanism complements compound Y in the following specific way" is a reason.
Are the dosing patterns and timing aligned with each compound's pharmacokinetics? A long-acting compound and a short-acting compound need different dosing patterns. Combining them on the same schedule wastes the long-acting compound's advantage and underdoses the short-acting compound's effects.
Is the combination supported by published research, or is it being investigated as a community experiment? Both can be legitimate but the framing should be honest. The CJC + ipamorelin combination has decades of pharmacological research and clinical use behind it. A novel combination of three or four compounds put together based on community speculation is a community experiment, not an evidence-based protocol — and should be approached as such.
What are the increased side effect or interaction risks? Combinations can produce effects neither compound produces alone. The cycling considerations also become more complex with multi-compound protocols.
What outcomes are being tracked? A protocol with five compounds and no measurable endpoint cannot generate useful data regardless of how well-designed the combination is.
The kitchen-sink stack problem.
Some protocols combine many compounds (six, eight, ten) without clear individual rationale for each. This is the kitchen-sink approach — "let me throw everything in and see what happens" is not a research design, it is enthusiasm. The Red Flags thread in this category covers the practice in more detail. The short version: more compounds is not better. A focused 2-3 compound combination with each compound chosen for a specific reason produces interpretable research; a 6-10 compound combination produces noise.
The pre-mixed product problem.
Some vendors sell pre-mixed combination products — "BPC + TB-500 blend," "CJC + ipa blend," "research recovery stack." These are problematic for several reasons covered in the Quality and Red Flags threads. The short version: there is no quality reason to buy pre-mixed. Mixing happens at the time of reconstitution; the buyer doing the mixing has full control over ratios and can verify each compound's quality independently. Pre-mixed products typically substitute cheaper compounds for the expensive ones in the labeled blend.
Where to go next.
The deeper threads in this category cover specific combinations. The recovery stack thread covers the four-compound BPC + TB-500 + GHK-Cu + ipamorelin protocol. The healing stack thread covers the three-compound BPC + TB-500 + GHK-Cu variant. The GLP-1 + GH secretagogues thread covers body recomposition combinations. The cycling thread covers when to take breaks and why. The Mechanism + Half-Life thread in this Research Library covers the pharmacology of stack design. The Quality and COA thread covers how to verify every compound in a multi-peptide protocol. The Red Flags thread covers the kitchen-sink and pre-mixed scam patterns.
